This investigation highlights SLC2A1 as a potentially valuable diagnostic and prognostic biomarker in AKI patients, offering novel functional implications and presenting it as a promising target for both diagnostic and therapeutic interventions. The gene discussed is SLC2A1; the disease is acute kidney injury.